Synapse - Advanced Practice Providers

Results (22)

Neratinib alone or in combination with immune checkpoint inhibitors with or without mammalian target of rapamycin inhibitors in patients with fibrolamellar carcinoma

Journal Article

Abou-Alfa, G. K.; Meyer, T.; Do, R. K. G.; Piha-Paul, S. A.; Light, J. S.; Sherrin, S.; Yaqubie, A.; O'Neill, A. C.; Harding, J. J.; Al-Rajabi, R.; more...
Liver Cancer (2025)

Fulltext@MSK | Save

Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC)

Meeting Abstract

Abou-Alfa, G. K.; Meyer, T.; Zhang, J.; Sherrin, S.; Yaqubie, A.; O'Neill, A. C.; Xu, F.; Eli, L. D.; Harding, J. J.; O'Reilly, E. M.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Extracellular vesicle and particle biomarkers define multiple human cancers

Journal Article

Hoshino, A.; Kim, H. S.; Bojmar, L.; Gyan, K. E.; Cioffi, M.; Hernandez, J.; Zambirinis, C. P.; Rodrigues, G.; Molina, H.; Heissel, S.; more...
Cell (2020)

Fulltext@MSK | Save

Binimetinib plus gemcitabine and cisplatin phase I/II trial in patients with advanced biliary cancers

Journal Article

Lowery, M. A.; Bradley, M.; Chou, J. F.; Capanu, M.; Gerst, S.; Harding, J. J.; El Dika, I.; Berger, M.; Zehir, A.; Ptashkin, R.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save

ADI-PEG 20 and FOLFOX6: A phase 1 study in pts (pts) with advanced hepatocellular carcinoma (HCC)

Meeting Abstract

Harding, J. J.; Do, R. K. G.; Hollywood, E.; Uhlitskykh, K.; Valentino, E.; Wan, P. J.; Hamilton, C. R.; Frick, J.; Feng, X.; Johnston, A.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis

Meeting Abstract

Yu, K. H.; Mantha, S.; Tjan, C.; Kaufmann, E. S.; Brenner, R.; Lowery, M. A.; Ku, G. Y.; Raj, N. P.; Shcherba, M.; Goldberg, Z.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis

Meeting Abstract

Yu, K.; Mantha, S.; Tjan, C.; Kaufmann, E.; Brenner, R. B.; Lowery, M.; Ku, G.; Raj, N.; Shcherba, M.; Goldberg, Z.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies

Journal Article

Harding, J. J.; Do, R. K.; El Dika, I.; Hollywood, E.; Uhlitskykh, K.; Valentino, E.; Wan, P.; Hamilton, C.; Feng, X.; Johnston, A.; more...
Cancer Chemotherapy and Pharmacology (2018)

Fulltext@MSK | Save

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma

Journal Article

Lowery, M. A.; Kelsen, D. P.; Capanu, M.; Smith, S. C.; Lee, J. W.; Stadler, Z. K.; Moore, M. J.; Kindler, H. L.; Golan, T.; Segal, A.; more...
European Journal of Cancer (2018)

Fulltext@MSK | Save

A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC)

Meeting Abstract

Lowery, M. A.; O'Reilly, E. M.; Harding, J. J.; Yu, K. H.; Cercek, A.; Hollywood, E.; Salehi, E.; Margona, E.; Bradley, M.; Witter, T.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save